Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib.
Liu Y, Lyu J, Bell Burdett K, Sibley AB, Hatch AJ, Starr MD, Brady JC, Hammond K, Marmorino F, Rossini D, Goldberg RM, Falcone A, Cremolini C, Owzar K, Ivanova A, Moore DT, Lee MS, Sanoff HK, Innocenti F, Nixon AB. Liu Y, et al. Among authors: nixon ab. Mol Cancer Ther. 2020 Oct;19(10):2146-2154. doi: 10.1158/1535-7163.MCT-20-0249. Epub 2020 Aug 3. Mol Cancer Ther. 2020. PMID: 32747417
Effect of pazopanib on tumor microenvironment and liposome delivery.
Tailor TD, Hanna G, Yarmolenko PS, Dreher MR, Betof AS, Nixon AB, Spasojevic I, Dewhirst MW. Tailor TD, et al. Among authors: nixon ab. Mol Cancer Ther. 2010 Jun;9(6):1798-808. doi: 10.1158/1535-7163.MCT-09-0856. Epub 2010 Jun 1. Mol Cancer Ther. 2010. PMID: 20515941 Free PMC article.
A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas.
Uronis HE, Bendell JC, Altomare I, Blobe GC, Hsu SD, Morse MA, Pang H, Zafar SY, Conkling P, Favaro J, Arrowood CC, Cushman SM, Meadows KL, Brady JC, Nixon AB, Hurwitz HI. Uronis HE, et al. Among authors: nixon ab. Oncologist. 2013;18(3):271-2. doi: 10.1634/theoncologist.2012-0404. Epub 2013 Mar 13. Oncologist. 2013. PMID: 23485624 Free PMC article. Clinical Trial.
Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment.
Hanks BA, Holtzhausen A, Evans KS, Jamieson R, Gimpel P, Campbell OM, Hector-Greene M, Sun L, Tewari A, George A, Starr M, Nixon AB, Augustine C, Beasley G, Tyler DS, Osada T, Morse MA, Ling L, Lyerly HK, Blobe GC. Hanks BA, et al. Among authors: nixon ab. J Clin Invest. 2013 Sep;123(9):3925-40. doi: 10.1172/JCI65745. Epub 2013 Aug 8. J Clin Invest. 2013. PMID: 23925295 Free PMC article.
A phase I study of ABT-510 plus bevacizumab in advanced solid tumors.
Uronis HE, Cushman SM, Bendell JC, Blobe GC, Morse MA, Nixon AB, Dellinger A, Starr MD, Li H, Meadows K, Gockerman J, Pang H, Hurwitz HI. Uronis HE, et al. Among authors: nixon ab. Cancer Med. 2013 Jun;2(3):316-24. doi: 10.1002/cam4.65. Epub 2013 Mar 21. Cancer Med. 2013. PMID: 23930208 Free PMC article. Clinical Trial.
Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.
Strickler JH, McCall S, Nixon AB, Brady JC, Pang H, Rushing C, Cohn A, Starodub A, Arrowood C, Haley S, Meadows KL, Morse MA, Uronis HE, Blobe GC, Hsu SD, Zafar SY, Hurwitz HI. Strickler JH, et al. Among authors: nixon ab. Invest New Drugs. 2014 Apr;32(2):330-9. doi: 10.1007/s10637-013-0042-9. Epub 2013 Nov 1. Invest New Drugs. 2014. PMID: 24173967 Free PMC article. Clinical Trial.
123 results